Upcoming Events

2nd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma

2nd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma

July 12 - 13, 2024 - Hilton Barcelona, Barcelona, Spain

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

In addition to which, this day and a half-long meeting will include sessions on:

  • Risk Stratification validation
  • Genomically targeted therapies
  • New technologies
  • Genomic Biomarkers for stratification of clinical studies
  • New clinical trials for patients with HR disease
21st IMS Annual Meeting

21st IMS Annual Meeting

September 25 - 28, 2024 - Rio de Janeiro, Brazil

Mark your calendars for the 21st IMS Annual Meeting in Rio de Janeiro, Brazil!

The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects.

This year’s program includes:

  • Six thematic sessions on:
    •  Precursor Disease
    •  Newly Diagnosed Multiple Myeloma
    •  High Risk Disease
    •  Relapsed: Treatments Outside of Immunotherapy
    •  Immunotherapy
    • Novel Biomarkers – personalizing therapy in myeloma
  • Talks and symposia on pressing topics led by the KOL of the myeloma community
  • Special Sessions for trainees and local attendees
  • Keynote addresses
  •  Joint sessions with regulatory agencies and other organisations
  • Special sessions on MRD and New Endpoints
  • Oral Abstracts (on Basic Biology, Preclinical Trials, and Clinical Studies)
  •  Poster Presentations
Educational Workshop Johannesburg, South Africa

Educational Workshop Johannesburg, South Africa

January 17 - 18, 2025 - Radisson Hotel & Convention Centre, Johannesburg, South Africa

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

6th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 28 - 29, 2025 - Boston Marriott Long Wharf, Boston, MA

IMS is pleased to announce that the 6th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 28-29, 2025 in Boston, MA.

More details will be available soon! 

Educational Workshop Marrakech, Morocco

Educational Workshop Marrakech, Morocco

April 25 - 26, 2025 - Radisson Blu Hotel, Marrakech Carre Eden

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Translational Research Award

Career Development Award

IMS Young Investigator Award

COMING SOON – ARTEMIS

About Our Publications

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

See All Publications

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events